Shen, Minhong
Wei, Yong http://orcid.org/0000-0002-1034-649X
Kim, Hahn
Wan, Liling
Jiang, Yi-Zhou
Hang, Xiang
Raba, Michael
Remiszewski, Stacy
Rowicki, Michelle
Wu, Cheng-Guo
Wu, Songyang
Zhang, Lanjing
Lu, Xin http://orcid.org/0000-0002-0284-6478
Yuan, Min
Smith, Heath A.
Zheng, Aiping
Bertino, Joseph
Jin, John F.
Xing, Yongna http://orcid.org/0000-0002-9834-528X
Shao, Zhi-Ming
Kang, Yibin http://orcid.org/0000-0002-1626-6730
Funding for this research was provided by:
U.S. Department of Defense (BC151403)
Article History
Received: 20 October 2020
Accepted: 23 September 2021
First Online: 29 November 2021
Competing interests
: Princeton has filed a disclosure on the findings based on this study. Y.K., M.S. and H.K. are named as co-inventors on the disclosure. J.F.J. is a cofounder, and Y.K. is a cofounder and chair of the scientific advisory board of Firebrand Therapeutics Inc., which has licensed relevant technologies from Princeton University to develop MTDH–SND1-targeting therapeutics. Y.K. is also a cofounder of Kayothera, Inc. and a member of the scientific advisory board for Cytocare, Inc. and Vibrant Pharma Limited. M. Raba is an employee of Crelux GmgH. S.R. is the owner of SWR Pharma Consulting LLC. The remaining authors declare no competing interests.